Healio

FDA allows Aerie to change primary endpoint range for Rocket 2 trial of Rhopressa

Please provide your email address to receive an email when new articles are posted on . The FDA has allowed Aerie Pharmaceuticals to change the primary endpoint range of Rocket 2, a second phase 3 ...
streetinsider

Aerie Pharma (AERI) Gets Positive Feedback from FDA on Rhopressa, to Modify Endpoint Range in Rocket 2 Trial

Aerie Pharmaceuticals, Inc. (NASDAQ: AERI) reported that the U.S. Food and Drug Administration (FDA) has agreed in written and verbal communications that Aerie may change the primary endpoint range of ...
BBC

How Endpoint claimed the Elite Series Rocket League crown

Endpoint beat Epsilon 4-2 in the final of the Gfinity Elite Series Rocket League competition to secure the inaugural title and a £20,000 cash prize. © 2024 BBC. The ...
Business Wire

Aerie Pharmaceuticals Initiates Fourth Phase 3 Clinical Trial of Rhopressa TM

The Rocket 4 clinical trial design includes the same clinical endpoint ranges used for our successful Rocket 2 clinical trial, from above 20 mmHg to below 25 mmHg, and is designed to provide ...